Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 88

1.

Unveiling the Biochemistry of the Epigenetic Regulator SMYD3.

Fabini E, Talibov VO, Mihalic F, Naldi M, Bartolini M, Bertucci C, Del Rio A, Danielson UH.

Biochemistry. 2019 Aug 21. doi: 10.1021/acs.biochem.9b00420. [Epub ahead of print]

PMID:
31389685
2.

Noelin1 Affects Lateral Mobility of Synaptic AMPA Receptors.

Pandya NJ, Seeger C, Babai N, Gonzalez-Lozano MA, Mack V, Lodder JC, Gouwenberg Y, Mansvelder HD, Danielson UH, Li KW, Heine M, Spijker S, Frischknecht R, Smit AB.

Cell Rep. 2018 Jul 31;24(5):1218-1230. doi: 10.1016/j.celrep.2018.06.102.

3.

Pan-NS3 protease inhibitors of hepatitis C virus based on an R3-elongated pyrazinone scaffold.

Belfrage AK, Abdurakhmanov E, Åkerblom E, Brandt P, Alogheli H, Neyts J, Danielson UH, Sandström A.

Eur J Med Chem. 2018 Mar 25;148:453-464. doi: 10.1016/j.ejmech.2018.02.032. Epub 2018 Feb 13.

PMID:
29477077
4.

Introduction of Intrinsic Kinetics of Protein-Ligand Interactions and Their Implications for Drug Design.

Linkuvienė V, Talibov VO, Danielson UH, Matulis D.

J Med Chem. 2018 Mar 22;61(6):2292-2302. doi: 10.1021/acs.jmedchem.7b01408. Epub 2018 Mar 2.

PMID:
29466001
5.

Characterization of interactions between hepatitis C virus NS5B polymerase, annexin A2 and RNA - effects on NS5B catalysis and allosteric inhibition.

Solbak SMØ, Abdurakhmanov E, Vedeler A, Danielson UH.

Virol J. 2017 Dec 11;14(1):236. doi: 10.1186/s12985-017-0904-4.

6.

Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase.

Abdurakhmanov E, Øie Solbak S, Danielson UH.

Viruses. 2017 Jun 16;9(6). pii: E151. doi: 10.3390/v9060151.

7.

Insights from engineering the Affibody-Fc interaction with a computational-experimental method.

Nosrati M, Solbak S, Nordesjö O, Nissbeck M, Dourado DFAR, Andersson KG, Housaindokht MR, Löfblom J, Virtanen A, Danielson UH, Flores SC.

Protein Eng Des Sel. 2017 Sep 1;30(9):593-601. doi: 10.1093/protein/gzx023.

PMID:
28472513
8.

Biophysical analysis of the dynamics of calmodulin interactions with neurogranin and Ca2+ /calmodulin-dependent kinase II.

Seeger C, Talibov VO, Danielson UH.

J Mol Recognit. 2017 Aug;30(8). doi: 10.1002/jmr.2621. Epub 2017 Apr 27.

9.

Monitoring drug-serum protein interactions for early ADME prediction through Surface Plasmon Resonance technology.

Fabini E, Danielson UH.

J Pharm Biomed Anal. 2017 Sep 10;144:188-194. doi: 10.1016/j.jpba.2017.03.054. Epub 2017 Mar 28. Review.

PMID:
28392047
10.

Let There Be Light!

Raykova D, Koos B, Asplund A, Gelléri M, Ivarsson Y, Danielson UH, Söderberg O.

Proteomes. 2016 Nov 29;4(4). pii: E36. doi: 10.3390/proteomes4040036. Review.

11.

Development of a novel therapeutic vaccine carrier that sustains high antibody titers against several targets simultaneously.

Saupe F, Reichel M, Huijbers EJ, Femel J, Markgren PO, Andersson CE, Deindl S, Danielson UH, Hellman LT, Olsson AK.

FASEB J. 2017 Mar;31(3):1204-1214. doi: 10.1096/fj.201600820R. Epub 2016 Dec 19.

PMID:
27993994
12.

Biophysics in drug discovery: impact, challenges and opportunities.

Renaud JP, Chung CW, Danielson UH, Egner U, Hennig M, Hubbard RE, Nar H.

Nat Rev Drug Discov. 2016 Oct;15(10):679-98. doi: 10.1038/nrd.2016.123. Epub 2016 Aug 12. Review.

13.

Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease.

Belfrage AK, Abdurakhmanov E, Kerblom E, Brandt P, Oshalim A, Gising J, Skogh A, Neyts J, Danielson UH, Sandström A.

Bioorg Med Chem. 2016 Jun 15;24(12):2603-20. doi: 10.1016/j.bmc.2016.03.066. Epub 2016 Apr 8.

PMID:
27160057
14.

Kinetically Selective Inhibitors of Human Carbonic Anhydrase Isozymes I, II, VII, IX, XII, and XIII.

Talibov VO, Linkuvienė V, Matulis D, Danielson UH.

J Med Chem. 2016 Mar 10;59(5):2083-93. doi: 10.1021/acs.jmedchem.5b01723. Epub 2016 Feb 8.

PMID:
26805033
15.

Analysis of the leakage of gene repression by an artificial TetR-regulated promoter in cyanobacteria.

Huang HH, Seeger C, Danielson UH, Lindblad P.

BMC Res Notes. 2015 Sep 19;8:459. doi: 10.1186/s13104-015-1425-0.

16.

Identification and Characterization of an Irreversible Inhibitor of CDK2.

Anscombe E, Meschini E, Mora-Vidal R, Martin MP, Staunton D, Geitmann M, Danielson UH, Stanley WA, Wang LZ, Reuillon T, Golding BT, Cano C, Newell DR, Noble ME, Wedge SR, Endicott JA, Griffin RJ.

Chem Biol. 2015 Sep 17;22(9):1159-64. doi: 10.1016/j.chembiol.2015.07.018. Epub 2015 Aug 27.

17.

Proximity-dependent initiation of hybridization chain reaction.

Koos B, Cane G, Grannas K, Löf L, Arngården L, Heldin J, Clausson CM, Klaesson A, Hirvonen MK, de Oliveira FM, Talibov VO, Pham NT, Auer M, Danielson UH, Haybaeck J, Kamali-Moghaddam M, Söderberg O.

Nat Commun. 2015 Jun 12;6:7294. doi: 10.1038/ncomms8294.

18.

Molecular blueprint of allosteric binding sites in a homologue of the agonist-binding domain of the α7 nicotinic acetylcholine receptor.

Spurny R, Debaveye S, Farinha A, Veys K, Vos AM, Gossas T, Atack J, Bertrand S, Bertrand D, Danielson UH, Tresadern G, Ulens C.

Proc Natl Acad Sci U S A. 2015 May 12;112(19):E2543-52. doi: 10.1073/pnas.1418289112. Epub 2015 Apr 27.

19.

Vinylated linear P2 pyrimidinyloxyphenylglycine based inhibitors of the HCV NS3/4A protease and corresponding macrocycles.

Lampa A, Alogheli H, Ehrenberg AE, Åkerblom E, Svensson R, Artursson P, Danielson UH, Karlén A, Sandström A.

Bioorg Med Chem. 2014 Dec 1;22(23):6595-6615. doi: 10.1016/j.bmc.2014.10.010.

PMID:
25456385
20.

Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2-P1' Region.

Lampa AK, Bergman SM, Gustafsson SS, Alogheli H, Akerblom EB, Lindeberg GG, Svensson RM, Artursson P, Danielson UH, Karlén A, Sandström A.

ACS Med Chem Lett. 2013 Aug 2;5(3):249-54. doi: 10.1021/ml400217r. eCollection 2014 Mar 13.

Supplemental Content

Loading ...
Support Center